.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD05_Sotrovimab.Sotrovimab .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06B_Immunoglobulins.J06BD05_Sotrovimab.Sotrovimab| name: | Sotrovimab |
| ATC code: | J06BD05 | route: | intravenous |
| n-compartments | 2 |
Sotrovimab is a recombinant human monoclonal antibody that targets the spike protein of SARS-CoV-2, the virus responsible for COVID-19. It is used for the treatment of mild-to-moderate COVID-19 in patients at risk of developing severe disease. Sotrovimab received Emergency Use Authorization (EUA) and conditional approvals in various countries during the COVID-19 pandemic.
Pharmacokinetic parameters derived from adult healthy volunteers and patients with mild to moderate COVID-19 infection.
Sager, JE, et al., & Reyes, M (2023). Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19. CPT: pharmacometrics & systems pharmacology 12(6) 853–864. DOI:10.1002/psp4.12958 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36922886
Boonyaratanakornkit, J, et al., & Waghmare, A (2024). The Effect of Gastrointestinal Graft-Versus-Host Disease and Diarrhea on the Pharmacokinetic Profile of Sotrovimab in Hematopoietic Stem Cell Transplant Recipients. The Journal of infectious diseases 230(3) 670–679. DOI:10.1093/infdis/jiae236 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38743457